AST (aspartate aminotransferase) is an enzyme released when liver, muscle, heart, or blood cells are damaged. Unlike ALT, which is liver-specific, AST also appears abundantly in skeletal and cardiac muscle, making it a marker of broader cellular injury. When AST and ALT rise together, it suggests hepatic damage; when AST rises alone or predominates, muscle injury or hemolysis is often the culprit. AST is routinely measured in Swedish vårdcentraler and is essential for distinguishing liver disease from other causes of transaminase elevation.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
AST testing is relevant if you have symptoms of liver injury (jaundice, right-upper-quadrant pain, dark urine), a history of hepatitis or heavy alcohol use, or unexplained fatigue. It is also ordered routinely as part of general health screening in Swedish vårdcentraler, particularly when ALT is elevated or when muscle symptoms (weakness, soreness after exercise, rhabdomyolysis risk) are present. AST answers a critical interpretive question: is the transaminase elevation a liver problem or something else?
The key clinical insight is that AST is not liver-specific. Its presence or elevation tells you that cellular damage has occurred somewhere in the body — but not automatically where. This is why AST is always interpreted in context with ALT, GGT, bilirubin, and clinical history. If you have risk factors for liver disease (alcohol, viral hepatitis, autoimmune hepatitis, cirrhosis family history) or unexplained enzyme elevation, AST is part of the diagnostic toolkit.
Clarifies hepatic vs non-hepatic injury. When paired with ALT, AST reveals whether transaminase elevation is truly hepatic or driven by muscle, hemolysis, or cardiac injury.
Flags muscle damage and hemolysis. Isolated AST elevation (with normal or low ALT) points to skeletal or cardiac muscle injury, rhabdomyolysis, or hemolysis in red blood cells, particularly after intense exercise or trauma.
Detects chronic liver disease severity. In established liver disease, the AST/ALT ratio rises — a ratio > 2 is a classic marker of alcoholic liver disease, while > 1 in chronic liver disease suggests advancing fibrosis or cirrhosis.
Monitors disease progression. Tracking AST over time in patients with known hepatitis, cirrhosis, or autoimmune liver disease helps guide therapy and detect acute decompensation.
Identifies transient confounders. AST spikes predictably after intense resistance training, eccentric exercise, muscle trauma, or hemolyzed blood samples — understanding these helps avoid unnecessary alarm or misdiagnosis.
Supports differential diagnosis. Elevated AST with normal bilirubin and normal or only mildly elevated ALT suggests muscle or hemolytic process rather than hepatocellular injury, refining the diagnostic picture.
The enzyme and its distribution. AST (aspartate aminotransferase) is a cytoplasmic enzyme that catalyzes the transamination of aspartate — a key step in amino acid metabolism and gluconeogenesis. It exists in mitochondrial and cytoplasmic pools in most tissues, with the highest concentrations in the liver, skeletal muscle, cardiac muscle, kidneys, and red blood cells. This broad distribution is why AST is sensitive to damage across multiple organ systems but lacks the specificity of ALT, which is predominantly hepatic.
Why AST rises and what it reveals. When cells are damaged or undergo rapid turnover (hepatocyte necrosis, myocyte rupture, hemolysis), AST leaks into the bloodstream. Because muscle tissue contains vastly more AST than liver tissue on a per-gram basis, intense exercise or muscle trauma can elevate AST 2–10-fold even without hepatic injury. Similarly, hemolyzed samples or in-vivo hemolysis (from severe anemia, sickle cell crisis, autoimmune hemolytic anemia) release red blood cell AST into plasma. The liver's contribution to AST elevation is real but must be distinguished from muscle, heart, and blood cell sources through interpretation alongside ALT, CK (creatine kinase), LDH, bilirubin, and clinical context.
The ALT vs AST pairing in clinical interpretation. In acute hepatocellular injury (viral hepatitis, drug-induced liver injury, acute alcoholic hepatitis), both AST and ALT rise sharply, often with ALT > AST. But in chronic liver disease and cirrhosis, AST progressively rises relative to ALT — the AST/ALT ratio flips. This shift occurs because hepatocyte necrosis in cirrhosis is ongoing and severe, and mitochondrial AST (which is preferentially released during more severe injury) becomes dominant. An AST/ALT ratio > 2 is classical for alcoholic cirrhosis; ratios > 1 in non-alcoholic liver disease often signal advancing fibrosis. This ratio is one of the most diagnostically useful pieces of information you can extract from the transaminase pair.
Identifies silent liver disease. Early-stage cirrhosis, chronic hepatitis, and fibrosis may not cause symptoms. AST elevation paired with GGT and bilirubin changes can flag hepatic disease before clinical decompensation, allowing early intervention.
Distinguishes injury patterns for targeted response. An isolated AST spike after intense training is benign and self-resolving; persistent AST elevation without exercise or trauma warrants investigation. The ability to read AST's context prevents both unnecessary anxiety and missed diagnosis.
Guides alcohol and medication safety. AST is exquisitely sensitive to hepatotoxic drugs and alcohol-related liver damage. Routine testing allows early detection of drug-induced liver injury (statins, acetaminophen, antibiotics) or alcoholic hepatitis before cirrhosis develops.
Monitors muscle integrity and hemolysis. In patients with autoimmune hemolytic anemia, muscular dystrophy, statin myopathy, or rhabdomyolysis risk, AST trends reveal whether muscle or red blood cell injury is accelerating, informing treatment decisions.
AST is measured in U/L (units per liter) using enzymatic assays standardized across Swedish clinical laboratories. Reference ranges vary slightly by laboratory and assay, but the ranges below represent current Swedish vårdcentral standard practice.
Standard Swedish reference (vårdcentralen): < 50 U/L for men; < 35 U/L for women. This is the standard “normal” range reported by most accredited Swedish laboratories.
Loovi optimal (longevity): < 35 U/L for all adults. This lower threshold reflects a more conservative, preventive approach — AST in the 35–50 range can be normal by strict criteria but may warrant investigation if persistent or rising, especially in non-athletes.
Caution zone (possible muscle or hemolytic process): > 50 U/L without proportional ALT elevation, or > 35 U/L if accompanied by hemolysis symptoms (jaundice, dark urine, fatigue from anemia) or recent intense exercise > 72 hours ago.
The critical context is that AST alone is not diagnostic. A 60 U/L result in a marathoner 24 hours post-race is reassuring; the same value in a sedentary person with no clear explanation is concerning. Always pair AST with ALT to assess the AST/ALT ratio, GGT for cholestasis, bilirubin for hemolysis or hepatic clearance, and clinical history.
Low AST (< 15 U/L). Rare and not usually clinically significant. Extreme deficiency of AST is associated with vitamin B6 (pyridoxine) deficiency, but this is uncommon in well-nourished populations. Very low AST may appear in chronic severe malnutrition or advanced liver disease with hepatocyte loss, but it is not independently actionable — interpret in full clinical context.
Normal AST (15–35 U/L in women; 15–50 U/L in men). Consistent with absent or minimal hepatic, muscle, or hemolytic injury. In young, healthy, sedentary adults, AST in this range reassures that major liver and muscle pathology are absent. In athletes or very physically active individuals, this range is expected even during training. If AST is normal but ALT or other markers are abnormal, interpret the pattern carefully.
Mildly elevated AST (35–100 U/L). This depends entirely on context. In a sedentary person with normal ALT and normal GGT, mild AST elevation may reflect muscle micro-trauma from recent activity, a hemolyzed sample, or early hepatic stress. In a person with risk factors for liver disease (alcohol, viral hepatitis, fatty liver, autoimmune disease), even mild AST elevation warrants ALT pairing and GGT assessment. If AST/ALT ratio is < 1 (ALT higher), acute hepatocellular injury is likely; if ratio > 1, chronic liver disease or muscle injury becomes more likely.
Markedly elevated AST (> 100 U/L). This demands investigation. AST > 100 reflects significant hepatic or extra-hepatic tissue damage. In acute viral or drug-induced hepatitis, AST may exceed 1000 U/L; in acute rhabdomyolysis, CK (not AST alone) will be markedly elevated and AST will follow. In acute alcoholic hepatitis or severe muscle injury from trauma, AST can reach 200–500 U/L. Immediately pair with ALT, bilirubin, albumin, GGT, and clinical history to determine the source and urgency.
Factors that influence AST. AST is highly responsive to transient muscle injury — intense resistance training, eccentric exercise, marathon running, or IM injections can elevate AST 2–10-fold for 24–72 hours. Hemolyzed blood samples (in vivo or during collection) falsely elevate AST and should trigger a redraw. Pregnancy is generally associated with minimal AST change. Acute illness (sepsis, severe infection), myocardial infarction, and seizures elevate AST acutely. Alcohol, if consumed heavily the night before testing, may elevate both AST and ALT, but the pattern is usually diffuse. Certain medications (acetaminophen, antibiotics, statins) can cause drug-induced liver injury with progressive AST rise. Timing of the blood draw relative to exercise matters — a draw within 12 hours of intense training will show higher AST than a draw at rest.
Hepatic causes. Viral hepatitis (A, B, C, EBV), alcoholic liver disease, drug-induced liver injury (acetaminophen overdose, amoxicillin-clavulanate, statins at high doses), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, primary biliary or primary sclerosing cholangitis, cirrhosis from any cause, hepatocellular carcinoma, and acute liver failure. In these conditions, AST usually rises with ALT, though the ratio and degree depend on the underlying pathology.
Muscle causes. Intense resistance training, eccentric exercise, marathon running, muscle trauma, rhabdomyolysis, myositis, muscular dystrophy, statin-induced myopathy, and crush injuries release AST from damaged myocytes. The AST may far exceed ALT, and CK will be even more elevated. After exercise, AST peaks 12–24 hours post-activity and returns to baseline within 72 hours.
Hemolytic causes. Autoimmune hemolytic anemia, hemoglobinopathies (sickle cell disease), microangiopathic hemolytic anemia (thrombotic thrombocytopenic purpura, hemolytic uremic syndrome), G6PD deficiency with oxidative stress, infections causing hemolysis, and transfusion reactions all release red blood cell AST. In these conditions, LDH and indirect bilirubin also rise; AST elevation is part of the hemolytic pattern, not isolated.
Cardiac causes. Acute myocardial infarction, myocarditis, cardiac trauma, and heart failure can elevate AST acutely. In MI, AST rises within 4–8 hours, peaks at 24–48 hours, and returns to baseline within 5–7 days. Troponin and CK-MB are more specific for cardiac injury.
Renal and other causes. Advanced renal failure may mildly elevate AST (unclear mechanism, possibly malnutrition or hemolysis). Hemolyzed samples or in-vivo hemolysis during phlebotomy falsely elevate AST and should trigger a redraw.
Hepatic optimization — the nutrition and lifestyle pillars. If AST elevation reflects liver stress, the primary levers are alcohol reduction or elimination, metabolic weight loss (if NAFLD is present), and reducing hepatotoxic exposures. Soluble fiber, plant polyphenols, and fish oils may improve hepatic fat content and reduce inflammation through improvements in insulin sensitivity and lipid metabolism — but these are supportive, not curative. Sleep deprivation and chronic stress impair hepatic lipid clearance and increase inflammation; prioritizing sleep and stress management supports liver health. Regular moderate aerobic activity improves hepatic fat metabolism and insulin sensitivity.
Muscle optimization — preventing transient elevation from exercise. AST elevation after intense training is expected, harmless, and temporary. To avoid misinterpretation, time your test at least 72 hours after your last intense resistance or eccentric workout. If you want to include recent training context in your test result interpretation, log it with your blood draw. Progressive strength training and recovery (adequate protein, sleep, hydration) minimize pathological muscle damage while building resilience; transient AST elevation is a normal adaptation signal, not a sign of injury.
Hemolytic disease — avoiding and monitoring hemolysis. If hemolysis is driving AST elevation (autoimmune hemolytic anemia, G6PD deficiency), management depends on the underlying cause and lies outside the scope of simple biomarker optimization. Work with your clinician on immunosuppression, infection avoidance, transfusion support, or splenectomy as appropriate. For sample-related hemolysis, ensure skilled phlebotomy and gentle sample handling — vigorous shaking or excessive tourniquet time causes in-vitro hemolysis and falsely elevates AST, GGT, and LDH.
Pharmacology — minimizing hepatotoxic drug effects. If AST is rising in the context of statins, acetaminophen, antibiotics, or NSAIDs, discuss dose reduction, switch, or discontinuation with your clinician. Statins are rarely hepatotoxic at standard doses, but they can elevate transaminases mildly; a 2–3× rise that plateaus and remains stable does not mandate stopping. Acetaminophen overdose or chronic high-dose use can cause severe hepatotoxicity — keep intake < 3 g/day and avoid combining with alcohol. Certain antiretrovirals, antituberculosis drugs, and antifungals carry higher hepatotoxicity risk and require close monitoring.
The right optimization path depends on whether your AST elevation is hepatic, muscular, hemolytic, or cardiac. A thorough evaluation by a longevity doctor — integrating AST with ALT, GGT, bilirubin, albumin, CK, and clinical context — identifies the true driver and targets intervention accordingly. That is what the Loovi consultation brings to the table.
AST in isolation is uninterpretable. Its strength is not in absolute value but in its relationship to ALT, GGT, bilirubin, albumin, and clinical history. An AST of 50 U/L in a marathoner 48 hours post-race is completely different from 50 U/L in a person with dark urine and jaundice. An AST/ALT ratio of 0.8 (ALT higher) suggests acute hepatitis; a ratio of 3.0 (AST higher) suggests cirrhosis or muscle injury — same AST value, opposite implications.
The Loovi membership tests 120+ biomarkers annually, not just AST. You get ALT (liver-specific), GGT (cholestasis and liver induction), alkaline phosphatase (ALP) (bone and hepatic), bilirubin (hemolysis and hepatic clearance), albumin (synthetic hepatic function), and complete metabolic panel context. You also track CK (muscle injury), LDH (hemolysis and tissue damage), and CBC (anemia and hemolysis). You combine blood work with physical testing — VO2 max, grip strength, mobility — that reveal muscle and cardiovascular fitness. And critically, you get unrushed 1-on-1 consultation with a longevity doctor who integrates all this data, asks about your recent training and alcohol intake, and tells you whether that AST elevation is benign or urgent. That is how you turn a single enzyme into actionable insight.
ALT is liver-specific — it is predominantly found in hepatocytes and barely present in muscle. AST is found everywhere. If only ALT is elevated, the injury is almost certainly hepatic. If AST is elevated but ALT is normal or low, the injury is likely muscle, hemolytic, or cardiac. Both should rise together in acute hepatitis. In chronic liver disease, AST rises faster and higher than ALT, flipping the ratio — this is the hallmark of cirrhosis. For pure liver health assessment, ALT is more specific; for detecting non-hepatic causes of enzyme elevation, AST is more informative.
This pattern strongly suggests muscle injury, hemolysis, or cardiac injury rather than liver disease. If you exercised intensely within the past 72 hours, muscle micro-injury and rhabdomyolysis are likely culprits. Check CK to confirm muscle damage. If you have jaundice, dark urine, or anemia symptoms, hemolysis is likely — check LDH and indirect bilirubin. If you have chest pain or dyspnea, cardiac injury is possible — check troponin and EKG. If none of these fit, retest ALT and AST to rule out a one-time hemolyzed sample. Persistent isolated AST elevation without a clear extrahepatıc source warrants specialist referral.
Yes. Intense resistance training, eccentric movements, and marathon running elevate AST 2–10-fold for 24–72 hours post-exercise. This is a normal adaptation signal — muscle micro-trauma triggers protein turnover and enzyme release. It is not a sign of injury. To avoid misinterpretation, time your Loovi test at least 72 hours after intense training. If you do test soon after a hard workout, tell your longevity doctor — the AST elevation will be expected and reassuring, not alarming.
A ratio > 2 (AST more than twice ALT) is a classic marker of alcoholic cirrhosis. Ratios > 1 in any chronic liver disease suggest advancing fibrosis or cirrhosis because mitochondrial AST — preferentially released during severe hepatocyte necrosis — becomes dominant. Ratios < 1 (ALT higher) suggest acute hepatocellular injury like viral hepatitis or drug-induced liver injury. The ratio is one of the most diagnostically useful pieces of information you can extract from transaminase pairs — do not ignore it.
Yes. Acetaminophen (especially overdose or chronic high-dose use), statins (rarely at standard doses), antibiotics like amoxicillin-clavulanate, NSAIDs, and certain antiretrovirals can cause drug-induced liver injury with AST elevation. If AST rises after starting a new medication and falls when you stop it, the drug is likely culprit. If AST remains elevated months after starting a medication and is stable, hepatic adaptation has occurred and stopping is usually not necessary — but discuss with your doctor. Acetaminophen is the most common cause of acute liver failure from drugs in developed countries — keep daily intake < 3 g and avoid combining with alcohol.
AST typically remains within normal range during uncomplicated pregnancy. If AST is elevated during pregnancy, it may indicate preeclampsia with liver involvement (HELLP syndrome), acute fatty liver of pregnancy, or coincidental hepatitis. Any AST elevation in pregnancy warrants urgent medical evaluation — these are serious conditions requiring obstetric specialist input.
If the elevation is from recent exercise, AST returns to baseline within 72 hours naturally — no intervention needed. If the elevation is from acute hepatitis or drug-induced liver injury, AST may fall over days to weeks as the insult resolves, or it may persist if the driver (alcohol, a hepatotoxic drug) continues. If the elevation is from cirrhosis, AST is unlikely to normalize — the goal is to stabilize or slow further rise through disease management (immunosuppression for autoimmune hepatitis, antiviral therapy for hepatitis B or C, alcohol cessation for alcoholic liver disease). The rate of AST change depends on the underlying biology — discuss timelines with your doctor based on the specific diagnosis.
Yes. AST is routinely measured as part of comprehensive metabolic panels in Swedish healthcare, especially in annual health checks and risk assessment. It is covered by Friskvårdsbidrag if ordered as part of preventive screening. Most vårdcentraler report AST as part of standard biochemistry testing, often alongside ALT, GGT, ALP, and bilirubin.
AST > 500 U/L suggests acute, severe tissue injury — acute hepatitis (viral or drug-induced), acute myocardial infarction, rhabdomyolysis, or acute severe hemolysis. This warrants urgent evaluation. Get to an emergency department or contact your doctor immediately. Do not delay. Tests to order urgently: ALT, bilirubin, albumin, INR, CK, LDH, troponin, EKG, and possibly abdominal ultrasound or CT to rule out acute liver failure, cardiac infarction, or rhabdomyolysis.
